tetano
Editor, Senior Moderator
Vaccine
. 2024 May 8:S0264-410X(24)00527-9.
doi: 10.1016/j.vaccine.2024.04.088. Online ahead of print. Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks
Deok-Hwan Kim[SUP] 1 [/SUP], Seung-Hun Lee[SUP] 2 [/SUP], Jiwon Kim[SUP] 2 [/SUP], Jiho Lee[SUP] 3 [/SUP], Jei-Hyun Jeong[SUP] 1 [/SUP], Ji-Yun Kim[SUP] 2 [/SUP], Seung-Un Song[SUP] 4 [/SUP], Hyukchae Lee[SUP] 2 [/SUP], Andrew Y Cho[SUP] 4 [/SUP], Ji-Yeon Hyeon[SUP] 4 [/SUP], Sungsu Youk[SUP] 5 [/SUP], Chang-Seon Song[SUP] 6 [/SUP]
Affiliations
A Newcastle disease virus (NDV)-vectored vaccine expressing clade 2.3.4.4b H5 Hemagglutinin was developed and assessed for efficacy against H5N1 highly pathogenic avian influenza (HPAI) in specific pathogen-free (SPF) chickens, broilers, and domestic ducks. In SPF chickens, the live recombinant NDV-vectored vaccine, rK148/22-H5, achieved complete survival against HPAI and NDV challenges and significantly reduced viral shedding. Notably, the live rK148/22-H5 vaccine conferred good clinical protection in broilers despite the presence of maternally derived antibodies. Good clinical protection was observed in domestic ducks, with decreased viral shedding. It demonstrated complete survival and reduced cloacal viral shedding when used as an inactivated vaccine from SPF chickens. The rK148/22-H5 vaccine is potentially a viable and supportive option for biosecurity measure, effectively protecting in chickens against the deadly clade 2.3.4.4b H5 HPAI and NDV infections. Furthermore, it aligns with the strategy of Differentiating Infected from Vaccinated Animals (DIVA).
Keywords: Broiler maternally-derived antibodies; Domestic ducks; H5N1 clade 2.3.4.4b; High pathogenic avian influenza; Newcastle disease virus-vectored vaccine.
. 2024 May 8:S0264-410X(24)00527-9.
doi: 10.1016/j.vaccine.2024.04.088. Online ahead of print. Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks
Deok-Hwan Kim[SUP] 1 [/SUP], Seung-Hun Lee[SUP] 2 [/SUP], Jiwon Kim[SUP] 2 [/SUP], Jiho Lee[SUP] 3 [/SUP], Jei-Hyun Jeong[SUP] 1 [/SUP], Ji-Yun Kim[SUP] 2 [/SUP], Seung-Un Song[SUP] 4 [/SUP], Hyukchae Lee[SUP] 2 [/SUP], Andrew Y Cho[SUP] 4 [/SUP], Ji-Yeon Hyeon[SUP] 4 [/SUP], Sungsu Youk[SUP] 5 [/SUP], Chang-Seon Song[SUP] 6 [/SUP]
Affiliations
- PMID: 38724417
- DOI: 10.1016/j.vaccine.2024.04.088
A Newcastle disease virus (NDV)-vectored vaccine expressing clade 2.3.4.4b H5 Hemagglutinin was developed and assessed for efficacy against H5N1 highly pathogenic avian influenza (HPAI) in specific pathogen-free (SPF) chickens, broilers, and domestic ducks. In SPF chickens, the live recombinant NDV-vectored vaccine, rK148/22-H5, achieved complete survival against HPAI and NDV challenges and significantly reduced viral shedding. Notably, the live rK148/22-H5 vaccine conferred good clinical protection in broilers despite the presence of maternally derived antibodies. Good clinical protection was observed in domestic ducks, with decreased viral shedding. It demonstrated complete survival and reduced cloacal viral shedding when used as an inactivated vaccine from SPF chickens. The rK148/22-H5 vaccine is potentially a viable and supportive option for biosecurity measure, effectively protecting in chickens against the deadly clade 2.3.4.4b H5 HPAI and NDV infections. Furthermore, it aligns with the strategy of Differentiating Infected from Vaccinated Animals (DIVA).
Keywords: Broiler maternally-derived antibodies; Domestic ducks; H5N1 clade 2.3.4.4b; High pathogenic avian influenza; Newcastle disease virus-vectored vaccine.